# Surviving PEA in Roanoke (SPEAR) Study

Study · id `cardio:ct-nct05283850` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05283850](<https://clinicaltrials.gov/study/NCT05283850>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05283850

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 342 participants.

## Technical summary

Registry record NCT05283850. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-16 (actual); primary completion 2027-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 342 participants (planned count; ClinicalTrials.gov record NCT05283850, source copy `cardio:ctgov-nct05283850-2022-03-17`, retrieved 2026-10-26)
- Started: 2022-02-16 (actual) (ClinicalTrials.gov record NCT05283850, source copy `cardio:ctgov-nct05283850-2022-03-17`, retrieved 2026-10-26)
- Primary completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT05283850, source copy `cardio:ctgov-nct05283850-2022-03-17`, retrieved 2026-10-26)
- Completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT05283850, source copy `cardio:ctgov-nct05283850-2022-03-17`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05283850, source copy `cardio:ctgov-nct05283850-2022-03-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05283850-2022-03-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Surviving PEA in Roanoke (SPEAR) Study
- Acronym: SPEAR
- Condition: Cardiac Arrest
- Condition: Pulseless Electrical Activity
- Intervention (Drug): High Calcium, Low Sodium (HCLS) Crystalloid Therapy
- Intervention (Drug): High Calcium, High Sodium (HCHS) Crystalloid Therapy
- Lead sponsor: Carol Bernier
- Lead sponsor class: OTHER
- Collaborator: Virginia Polytechnic Institute and State University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Sudden cardiac arrest (`cardio:sudden-cardiac-arrest`)

## Provenance

Content hash: a8d126c2e9b8886cbd42e16dfb63410e998b45ddb26b48f37687dc098ee8f346
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
